Skip to Content
Merck
All Photos(1)

Documents

P3487

Sigma-Aldrich

Monoclonal Anti-PTEN antibody produced in mouse

~1 mg/mL, purified immunoglobulin, clone PTN-18, buffered aqueous solution

Synonym(s):

Anti-Mutated in multiple advanced cancers 1, Anti-PTEN1, Anti-PTENbeta, Anti-Phosphatase and tensin homolog, Anti-TEP1

Sign Into View Organizational & Contract Pricing


About This Item

MDL number:
UNSPSC Code:
12352203
NACRES:
NA.41

biological source

mouse

conjugate

unconjugated

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

PTN-18, monoclonal

form

buffered aqueous solution

mol wt

antigen ~55 kDa

species reactivity

mouse, human, rat

concentration

~1 mg/mL

technique(s)

immunocytochemistry: suitable using 4% paraformaldehyde-0.5% Triton X-100 fixation
indirect ELISA: suitable
microarray: suitable
western blot: 5-10 μg/mL using whole extract of rat brain

isotype

IgG2a

UniProt accession no.

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... PTEN(5728)
mouse ... Pten(19211)
rat ... Pten(50557)

General description

The PTEN (phosphatase and tensin homolog) gene is mapped to human chromosome 10q23. It shares sequence homology with protein tyrosine phosphatases and the cytoskeletal protein tensin.

Specificity

The epitope recognized by the antibody resides within amino acids 386-403 of rat PTEN.

Immunogen

synthetic peptide corresponding to the C-terminus of rat PTEN (amino acids 386-403).

Biochem/physiol Actions

The PTEN (phosphatase and tensin homolog) gene encodes a encodes a dual-specificity phosphatase that functions as a tumor suppressor by inhibiting phosphoinositide-3-kinase–protein kinase B/Akt (PI3K/PKB/Akt) signaling pathway, a crucial regulator of cell growth and survival and by negatively regulating the interactions of cell with the extracellular matrix. Mutations in this gene have been associated with several human cancers. Germline mutations in this gene have also been linked to Cowden disease (CD), Lhermitte-Duclos disease (LDD) and Bannayan-Zonana syndrome (BZS), which are characterized by increased susceptibility to tumor formation and developmental defects.

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 1% BSA and 15 mM sodium azide.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN.
Tamura M, et al.
Science, 280(5369), 1614-1617 (1998)
Pten is essential for embryonic development and tumour suppression.
Di Cristofano A, et al.
Nature Genetics, 19(4), 348-355 (1998)
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN.
Stambolic V, et al.
Cell, 95(1), 29-39 (1998)
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.
Li J, et al.
Science, 275(5308), 1943-1947 (1997)
Ioannis Kalogiannidis et al.
Archives of gynecology and obstetrics, 290(6), 1231-1237 (2014-07-16)
To define the prognostic significance of HER-2/neu and PTEN expression in patients with endometrioid (type I) endometrial cancer. Seventy-seven patients with endometrioid endometrial carcinoma were included in the study, in a period between 1996 and 2009. Patients with coexisting malignancy

Articles

Quantitative and qualitative western blotting to validate knockdown by esiRNA.

Cancer stem cell media, spheroid plates and cancer stem cell markers to culture and characterize CSC populations.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service